JPMorgan Chase & Co. set a GBX 6,500 ($84.67) target price on AstraZeneca (LON:AZN) in a report published on Tuesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

AZN has been the subject of several other research reports. UBS Group reiterated a neutral rating and issued a GBX 5,600 ($72.95) price target on shares of AstraZeneca in a research report on Monday, July 2nd. Deutsche Bank reduced their price target on shares of AstraZeneca from GBX 6,000 ($78.16) to GBX 5,700 ($74.25) and set a buy rating for the company in a research report on Friday, July 20th. BNP Paribas set a GBX 6,500 ($84.67) price target on shares of AstraZeneca and gave the company a buy rating in a research report on Tuesday, September 11th. Barclays set a GBX 6,500 ($84.67) price target on shares of AstraZeneca and gave the company a buy rating in a research report on Friday, July 27th. Finally, Jefferies Financial Group set a GBX 6,200 ($80.76) price target on shares of AstraZeneca and gave the company a neutral rating in a research report on Thursday, August 16th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the company’s stock. AstraZeneca has an average rating of Hold and a consensus target price of GBX 5,689.45 ($74.11).

AZN stock opened at GBX 5,878 ($76.57) on Tuesday. AstraZeneca has a 12 month low of GBX 4,260 ($55.49) and a 12 month high of GBX 5,520 ($71.90).

The company also recently disclosed a dividend, which was paid on Monday, September 10th. Shareholders of record on Thursday, August 9th were paid a GBX 68.40 ($0.89) dividend. The ex-dividend date of this dividend was Thursday, August 9th. This represents a yield of 1.19%.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: Hedge Funds – How They Work For Investors

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.